Condition
Metastatic Prostate Cancer (mPC)
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Early P 1 (1)
Trial Status
Recruiting2
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06762379RecruitingPrimary
Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration
NCT06866782Recruiting
European Registry of Next Generation Imaging in Advanced Prostate Cancer
NCT06864572Early Phase 1Enrolling By InvitationPrimary
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
Showing all 3 trials